The discovery of induced pluripotent stem cells (iPSCs) a decade ago, which we are celebrating in this issue of Cell, represents a landmark discovery in biomedical research. Together with somatic cell nuclear transfer, iPSC generation reveals the remarkable plasticity associated with differentiated cells and provides an unprecedented means for modeling diseases using patient samples. In addition to transcriptional and epigenetic remodeling, cellular reprogramming to pluripotency is also accompanied by a rewiring of metabolic pathways, which ultimately leads to changes in cell identities.
The discovery of induced pluripotent stem cells (iPSCs) a decade ago, which we are celebrating in this issue of Cell, represents a landmark discovery in biomedical research. Together with somatic cell nuclear transfer, iPSC generation reveals the remarkable plasticity associated with differentiated cells and provides an unprecedented means for modeling diseases using patient samples. In addition to transcriptional and epigenetic remodeling, cellular reprogramming to pluripotency is also accompanied by a rewiring of metabolic pathways, which ultimately leads to changes in cell identities.
Cellular metabolism involves a set of complex and highly coordinated life-sustaining biochemical reactions that convert or use energy to maintain the living state of cells. Cellular metabolism has long been considered as a consequence, rather than a driver, of cell-fate changes-a view that has recently been challenged by its intrinsic links to epigenetic modifications of chromatin during development, disease progression, and cellular reprograming. In this Review, we will first summarize what we have learned about metabolic pathways characteristic of pluripotent stem cells (PSCs). We will then discuss metabolic reprograming to induced pluripotency and the modeling of metabolic diseases with iPSCs.
Metabolism and Different States of Pluripotency
Early mammalian development is accompanied by the establishment and loss of pluripotency, a transient property enabling epiblast cells to generate all tissues of an adult organism including the germ cells. Pluripotency first arises after the second cell-fate determination, when the inner cell mass (ICM) consolidates into two lineages: the extraembryonic primitive endoderm and the pluripotent epiblast. Embryonic pluripotency can be captured in vitro in the form of PSCs. PSCs retain the differentiation capability of epiblast cells while acquiring an unlimited self-renew potential in culture. In addition to the epiblast, PSCs can also be generated through culture adaptation of primordial germ cells (Matsui et al., 1992; Resnick et al., 1992) or nuclear reprograming methods, including somatic cell nuclear transfer (SCNT) (Tachibana et al., 2013) , transcription factorinduced reprograming (Takahashi and Yamanaka, 2006; Takahashi et al., 2007) , and chemical reprogramming (Hou et al., 2013) . For simplicity's sake, in this section we will discuss PSCs generated through nuclear reprograming alongside embryo-derived PSCs.
In contrast to somatic cells, PSCs show higher rates of glycolysis and lower levels of mitochondria metabolism marked by a reduced mitochondrial content and a lower inner mitochondrial membrane potential (DJ m ) (Chung et al., 2007; Folmes et al., 2011; Panopoulos et al., 2012; Prigione et al., 2010 Prigione et al., , 2011 Ryall et al., 2015; Van Blerkom, 2009; Varum et al., 2011; Warburg, 1956; Xu et al., 2013; Zhang et al., 2011; Zhu et al., 2010) . This glycolytic requirement of PSCs mirrors in vivo epiblast cells, indicating that the metabolic feature(s) of early embryonic cells can be recapitulated in cultured PSCs. Analogy has often been made between PSCs and cancer cells, which utilize aerobic glycolysis as the preferred metabolic pathway for faster ATP generation and the production of cellular building blocks, including nucleotide, amino acids, and lipids, to meet the anabolic demands of high proliferative growth. However, it becomes increasingly clear that glycolysis in PSCs is not operating in the exact same way as in cancer cells. Whereas in cancer cells aerobic glycolysis directs pyruvate toward lactate, PSCs show increased conversion of glucose to acetyl-coenzyme A (CoA), thereby providing substrates for histone acetylation to maintain the pluripotency program (Moussaieff et al., 2015) .
The ability for PSCs to indefinitely self-renew in vitro enables the identification of pluripotency-related metabolic signatures at a resolution not possible with primary epiblast cells. By taking an untargeted metabolomics approach, Yanes et al. revealed a metabolic signature of mouse embryonic stem cells (mESCs) characterized by an abundance in highly unsaturated endogenous metabolites whose levels decreased upon differentiation due to oxidation (Yanes et al., 2010) . Wang et al. profiled common metabolites and uncovered a unique threonine-dependent catabolism mediated by threonine dehydrogenase (TDH) in mESCs (Wang et al., 2009 ). Threonine provides a substantial supply of cellular glycine that facilitates one-carbon metabolism for enhanced purine biosynthesis to meet the mESCs' high nucleotide demand for rapid genome replication. In addition, TDH-mediated threonine catabolism also generates acetylCoA, which is essential for S-adenosylmethionine (SAM) synthesis, the main source of cellular methyl groups (Shyh-Chang et al., 2013) (Figure 1 ). SAM levels in turn affect H3K4me3 levels, thereby linking the threonine metabolic pathway to mESC pluripotency. Interestingly, Tdh is also expressed in ICM cells of early mouse embryos, and the growth of mouse embryos depends on threonine (Wang et al., 2009) , further confirming the efficacy of using cultured PSCs as a proxy for understanding the metabolic infrastructure of in vivo embryonic cells. In contrast to mouse, however, TDH is a non-functional pseudogene in humans. Human PSCs (hPSCs) utilize methionine instead of threonine to generate SAM, maintain H3K4me3 levels, and stay in the undifferentiated state (Shiraki et al., 2014) (Figure 1 ). Moussaieff et al. performed high-resolution nuclear magnetic resonance (NMR) and identified 44 metabolites and a metabolic transition during early hPSC differentiation marked by the rapid loss of glycolysis-derived acetyl-CoA that resulted in histone deacetylation and loss of pluripotency (Moussaieff et al., 2015) . These studies revealed an important link between cellular metabolism and the epigenetic regulation of pluripotency. Many cellular metabolites, such as acetyl-CoA, nicotinamide adenine dinucleotide (NAD + ), and SAM, are capable of diffusing through nuclear pores and serve as substrates or cofactors for various epigenome-modifying enzymes. Their abundance and intracellular localization may affect the efficacy and specificity of the epigenetic modifications that govern pluripotency.
Embryonic pluripotency exists in a continuum of time and space in epiblast cells of different temporal and topological origins. Nascent epiblast cells sit atop the pluripotency landscape, harboring an unbiased developmental potential toward all lineages of the embryo proper. Following implantation, epiblast cells rapidly increase in numbers and expand in space. In mice, at later stages, epithelialized epiblast forms together with extraembryonic tissues a highly polarized and complex structure known as the egg cylinder. Guided by developmental signals emanating from the surrounding extraembryonic lineages, regional patterns start to emerge in epiblast cells from different embryological locations. Although epiblast cells gradually become more restricted in their developmental potential, they remain pluripotent until gastrulation, when they differentiate into multipotent early lineage progenitors. Different phases of embryonic pluripotency, e.g., naive and primed, can be stabilized in culture in discrete pluripotent states Wu and Izpisua Belmonte, 2015a) . Naive pluripotency is defined by the unbiased developmental potential to form all somatic cell lineages and the germ cells, a property of nascent epiblast cells that can be recapitulated in vitro in mESCs. Consequently, chimera formation upon blastocyst injection is often used as a functional criterion to evaluate naive pluripotency of cultured PSCs. The term primed pluripotency, on the other hand, was first introduced to describe a phase of pluripotency characteristic of post-implantation epiblast cells that are poised for lineage differentiation. Primed plurpotency has also been captured in cell culture in the form of mouse epiblast stem cells (mEpiSCs) (Brons et al., 2007; Tesar et al., 2007) . Primed mEpiSCs are inefficient in generating blastocyst chimeras but instead can efficiently engraft to post-implantation epiblast and form ex vivo epiblast chimeric embryos, which has been recently used as a functional test for primed pluripotency (Huang et al., 2012 ; Kojima et al., Naive and primed PSCs differ in several metabolic features. When compared to primed cells, naive PSCs are associated with elevated mitochondrial function, increased OXPHOS, and a lower level of glycolysis. Several factors, including HIF1a, LIN28, and NNMT, have been involved in metabolic transition from naïve-toprimed pluripotent states. STAT3, on the other hand, drives OXPHOS in naive mESCs and facilitates metabolic resetting during primed-to-naive state transition.
2014; Wu et al., 2015) . Besides developmental potentials, naive and primed PSCs differ in colony morphology, single cell cloning efficiency, and transcriptomic and epigenetic features (Hackett and Surani, 2014; Wu and Izpisua Belmonte, 2015a) . Recent evidence also points to distinct metabolic programs that support naive and primed pluripotent states (Figure 1 ). It should be noted that although human ESCs are derived from pre-implantation blastocysts (Thomson et al., 1998) , they are considered ''primed'' because of the many defining molecular and functional features they share with mEpiSCs. Although naive mESCs are more glycolytic than somatic cells, they exhibit significantly lower extracellular acidification rate (ECAR), a measure of glycolytic activity, than primed mEpiSCs. One of the drivers of the highly glycolytic state in mEpiSCs is HIF1a. Both HIF1a and its targets (e.g., PDK1) are more enriched in mEpiSCs than in mESCs. Importantly, stabilization of HIF1a in mESCs induced a morphological and metabolic shift toward mEpiSCs (Zhou et al., 2012) . Unlike glycolysis, OXPHOS levels are higher in naive mESCs than in primed mEpiSCs. The higher OXPHOS activity observed in naive mESCs is, in part, driven by STAT3, a downstream effector of the LIF (leukemia inhibitor factor)-dependent self-renewal pathway. STAT3 also facilitated metabolic resetting during primed-to-naive state transition (Carbognin et al., 2016) . On the other hand, Zhang et al. identified LIN28 as an OXPHOS suppressor in primed PSCs and key regulator during the metabolic transition from naïve-to-primed pluripotent state . Through a series of ''omic'' analyses, the authors demonstrated that LIN28 maintained low mitochondrial function in primed cells, in part through binding to mRNAs encoding OXPHOS components and repression of their translation Mathieu and Ruohola-Baker, 2016) . Considering their roles in regulating OXPHOS, it'll be interesting to examine the interplay between LIN28 and STAT3 during metabolic transitions between naive and primed pluripotent states. The reduced mitochondrial respiration in mEpiSCs can also be attributed to, besides LIN28, a lower DJ m due to deficiency in electron transport chain complex IV cytochrome c oxidase (COX) and lower expression of Sco2, PGC-1b, and Esrrb genes (Zhou et al., 2012) . Other mechanisms by which ATP production by OXPHOS may be limited in primed mEpiSCs include high levels of hexokinase II, inactive pyruvate dehydrogenase (PDH), and the mitochondrial export of four carbon TCA cycle intermediates by mitochondrial uncoupling protein 2 (UCP2) (Varum et al., 2011; Vozza et al., 2014; Zhang et al., 2011) . It should be noted that although mEpiSCs show lower levels of mitochondrial respiration, they have higher mitochondrial DNA (mtDNA) copy number and more mature mitochondria than mESCs. The more developed mitochondria in primed pluripotent cells may serve as preparation for the elevated OXPHOS activities acquired upon differentiation (Folmes et al., 2012) . Interestingly, albeit at low levels, Tohyama et al. uncovered an indispensible role of OXPHOS in primed hPSCs' survival and identified glutamine as its major energy source (Tohyama et al., 2016) . Glutamine metabolism was also found to be important for maintaining hESC pluripotency through regulating OCT4 stability (Marsboom et al., 2016) . Similarly, mEpiSCs couldn't proliferate without glutamine supplementation (Carey et al., 2015) . Future studies are warranted to further understand the roles of OXPHOS in primed PSCs.
Several practical advantages associated with the naive state of pluripotency (including high single-cell survival rate, facile genome-editing capacity, and competency for chimera formation) have fueled the hunt for generating stable hPSCs analogous to naive mESCs in culture (Wu and Izpisua Belmonte, 2015a) . Unexpectedly, a number of medium formulations confer cultured hPSCs with naive features characteristic of mESCs (Chan et al., 2013; Duggal et al., 2015; Gafni et al., 2013; Guo et al., 2016; Hayashi and Surani, 2009; Theunissen et al., 2014; Wang et al., 2014a; Ware et al., 2014) . These naive features include a domed colony morphology, LIF dependence, preferential usage of the OCT4 distal enhancer, and a hypomethylated genome, among others (Wu and Izpisua Belmonte, 2015a) . Metabolic features have also been examined in naive hPSCs. Ware et al. observed significantly higher expression of COX subunits and ESRRB in naive hPSCs cultured in 2iF medium (2i plus FGF2) compared to primed hPSCs (Ware et al., 2014) . Also, 2iF-hPSCs displayed less mature mitochondria, characterized by round morphology with fewer cristae, in contrast to elongated and more developed cristae found in primed hPSCs. Naive hPSCs could also be obtained through genetic resetting of primed hPSCs or through de novo derivation from human blastocysts using t2iGö culture (2i with Gö 6983) (Guo et al., 2016; Takashima et al., 2014) . Compared to primed hPSCs, t2iLGö -hPSCs exhibited higher basal oxygen consumption rate (OCR) and electron transport chain activity, elevated expression of COX gene family members, and a reduced sensitivity to glycolysis inhibition by 2-deoxyglucose treatment, metabolic features reminiscent of naive mESCs (Takashima et al., 2014) . Low expression of COX gene family members was also observed in naive hPSCs cultured in 5iLA medium (5 chemical inhibitors [5i] , LIF, and Activin-A) (Sperber et al., 2015; Theunissen et al., 2014) . More recently, Sperber et al. used a systematic approach to profile the metabolic state of naive hPSCs and identified distinct metabolite compositions between primed hPSCs and 2iF-hPSCs, reflecting differential lipid and amino acid metabolisms (Sperber et al., 2015) . This study also revealed that nicotinamide N-methyltransferase (NNMT), which uses SAM as substrate, was highly expressed in naive 2iF-hPSCs, thereby helping to maintain low SAM and H3K27me3 levels. In line with this observation, downregulation of NNMT triggered the naive-to-primed state transition in hPSCs (Sperber et al., 2015; Wu and Izpisua Belmonte, 2015b) . Different extrinsic and/or intrinsic factors may nudge naive PSCs into distinct pluripotent sub-states that can be distinguished by epigenetic and metabolic features (Table 1) . In initial studies, a complex regime was used for culturing mESCs, which included fetal calf serum (FBS) and a supportive ''feeder'' layer of mitotically inactivated mouse embryonic fibroblasts (MEFs) (Evans and Kaufman, 1981; Martin, 1981) . Later studies identified LIF as the feeder substitute, which allowed mESC selfrenewal in the feeder-free serum/LIF (SL) condition (Smith et al., 1988; Williams et al., 1988) . mESCs grown in SL, also known as conventional mESCs or serum mESCs, exhibit morphological, molecular, and functional heterogeneities (Chambers et al., 2007; Hackett and Surani, 2014; Hayashi et al., 2008; Toyooka et al., 2008) largely due to complex and often conflicting signaling molecules contained in poorly defined serum preparations. Improved understanding of the signaling pathways regulating pluripotency led to the development of the ground-state culture (2iL) consisting of LIF and two chemical inhibitors: CHIR99021 (CHIR), a GSK3 kinase inhibitor, and PD0325901 (PD03), a MAPK/ERK inhibitor . 2iL culture greatly facilitates the derivation and routine maintenance of mESCs. Of note is that the SL culture only supported ESC derivation from the inbred 129 mouse strain, whereas ground-state culture enabled the efficient derivation of ESCs from all of the tested mouse strains, including non-permissive strains such as non-obese diabetic (NOD) ). Importantly, ground-state culture also supported the derivation of genuine rat ESCs capable of generating germline chimeras, a remarkable achievement 27 years after the initial mESCs were derived (Buehr et al., 2008; Li et al., 2008) . Interestingly, mESCs cultured in 2iL, but not SL, displayed substantial endogenous glucose-dependent glutamate production and could proliferate robustly without exogenous supply of glutamine (Carey et al., 2015) . In addition, with the exception of a-ketoglutarate (aKG), steady-state levels of TCA cycle metabolites were diminished in 2iL culture (Carey et al., 2015) . Under 2iL culture, both glucose and glutamine catabolism helped to maintain an elevated aKG/succinate ratio that promoted a hypomethylated epigenome (Carey et al., 2015) . These results suggest that 2iL culture induced a metabolic rewiring and reflect a change in cellular state within the realm of naive pluripotency, which is paralleled by distinct transcriptome and epigenome profiles between 2iL-and SL-ESCs (Marks et al., 2012) . 2iL culture supports a cellular phenotype that closely resembles the developmental ground state in the ICM cells, which is characterized by homogenous expression of key pluripotency factors and a less restricted epigenome (Hackett and Surani, 2014) . Similarly, 2iL-ESCs harbor a hypomethylated genome and significantly reduced expression of lineage-specific genes. In contrast, SL culture nudges mESCs into a more committed naive pluripotent state with higher expression of lineage-affiliated genes and a less permissive epigenetic landscape (Marks et al., 2012) . Distinct metabolic features in naive ESCs driven by changes in culture parameters suggest that a spectrum of metabolic substates can be achieved by culture adaptation of mESCs. In this regard, a recent study showed that supplementation of vitamin C, a potential cofactor for the Tet enzyme, induced an ICM-like DNA methylation state in cultured mESCs (Blaschke et al., 2013) . It will be interesting to determine whether the metabolic profile of mESCs cultured in vitamin C differs from those of 2iL-and SL-ESCs. The naive sub-state concept is particularly (Scognamiglio et al., 2016) . Diapause is used as a reproductive strategy in mouse to survive through unfavorable environmental conditions, and mouse embryos undergoing diapause exhibit little to no cell division and biosynthetic quiescence (Renfree and Shaw, 2000) . Interestingly SLmESCs expressed significantly higher levels of Myc transcripts compared to 2iL-ESCs, and Myc levels in naive hESCs were found lower than in primed hESCs (Scognamiglio et al., 2016) .
In this regard, it may be interesting to examine the connection between Myc levels, metabolism, and different pluripotent states. Pluripotent sub-states have also been described for primed PSCs. During the process of optimizing culture parameters for epiblast explants, our group has discovered a novel primed PSC type that can be efficiently captured in vitro by a combination of FGF2, IWR1 (a WNT/b-catenin pathway inhibitor), and serum-free culture (Wu et al., 2015) . These cells were designated as region-selective EpiSCs, or rsEpiSCs, largely due to their preferential engraftment to the posterior part of the post-implantation epiblast. rsEpiSCs harbor a high single-cell cloning efficiency, quite unusual for primed PSCs that normally survive poorly after single-cell dissociation, and proliferate at a faster pace than both mESCs and mEpiSCs. Metabolically rsEpiSCs were found to be even more glycolytic and exhibited lower OXOPHO activity than mEpiSCs. Untargeted metabolomic and lipidomic analyses identified several hundred metabolites with significantly different abundance between rsEpiSCs and mEpiSCs. This unique metabolic state of rsEpiSCs may help support the epithelial-to-mesenchymal transition (EMT) during gastrulation, when posterior-proximal epiblast cells delaminate and ingress through the primitive streak to form mesoendoderm. Examining several markers of the EMT process revealed reduced levels of E-CADHERIN and CLAUDIN3 proteins and elevated levels of SNALIL in During cellular reprogramming, somatic cells exhibit an increase in the rate of glycolysis through an increase in the expression of glycolytic genes and an upregulation of glycolytic pathways. Concomitantly, mitochondrial metabolism is decreased through a downregulation of mitochondrial genes and reduced mitochondrial density, leading to decreased oxygen consumption. These changes, which are necessary to sustain a pluripotent state, are reversed when iPSCs are differentiated, allowing cells to acquire specialized functions.
rsEpiSCs (Wu et al., 2015) , suggesting that the EMT process may have been initiated in cultured rsEpiSCs. Therefore, rsEpiSCs may serve as an in vitro model for studying metabolic dynamics during gastrulation.
Stem cell differentiation provides an unprecedented means for studying development in vitro (Wu and Izpisua Belmonte, 2016) . Cellular metabolism undergoes significant changes during the differentiation process (Figure 2) . In contrast to PSCs, higher amounts of energy and lower levels of anabolic precursors are needed to maintain the highly specialized function of somatic cells (Folmes et al., 2012) . Because of the essential roles played by mitochondria in energy production, mitochondria also undergo significant changes during cellular differentiation. These changes include downregulation of glycolytic enzymes, upregulation of enzymes of the TCA cycle and subunits of the mitochondrial respiratory chain, an increase in oxygen consumption, and significant alterations in mitochondrial structure and morphology (Chung et al., 2010; Facucho-Oliveira et al., 2007; Mandal et al., 2011; Prigione et al., 2010; Suhr et al., 2010) . Consequently, a metabolic transition from glycolysis to OXPHOS is observed during cellular differentiation. Importantly, changes in mitochondrial metabolism are not only necessary to sustain cellular differentiation but act as drivers that initiate and promote the differentiation process through multiple signaling pathways (Hamanaka et al., 2013; Kasahara et al., 2013; Tormos et al., 2011; Yanes et al., 2010) . Supporting this transition, inhibition of glycolytic enzymes' activities enhanced cellular differentiation, whereas inhibition of mitochondrial function (using inhibitors of the mitochondrial respiratory chain) impaired differentiation (Chung et al., 2010; Mandal et al., 2011) .
Although the complex mechanisms responsible for the rapid transition between metabolic states during cellular differentiation remain unclear, Zhang et al. demonstrated that UCP2 regulated the coupling of mitochondrial respiration and energy production in somatic cells and PSCs. High levels of UCP2 uncoupled respiration in PSCs, but a significant downregulation of UCP2 was observed during cell differentiation (Zhang et al., 2011) . Along the same lines, maintaining high UCP2 levels impaired the differentiation capacity of PSCs, reinforcing the role of metabolism during cellular differentiation. Zhang et al. initially proposed the shunting away of pyruvate by UCP2, similar to that of UCP1, from the oxidation in mitochondria toward the pentose phosphate pathway as a mechanism for the uncoupling of respiration in PSCs. Nevertheless, a later study by Vozza et al. used a human hepatocellular carcinoma line to demonstrate that UCP2 regulates glucose and glutamine oxidation by transporting four carbon metabolites out of mitochondria (Vozza et al., 2014) . Similarly, Hom et al. demonstrated that closing of the mitochondrial permeability transition pore (mPTP) was critical during cardiomyocyte differentiation. An open mPTP during pluripotency uncoupled cellular respiration and energy production, whereas progressive mPTP closure was necessary for cardiomyocyte differentiation (Hom et al., 2011) . Understanding the unique metabolic changes associated with cardiomyocyte differentiation has enabled the development of methods for the large-scale purification of cardiomyocytes. Based on differences in glucose and lactate metabolism between PSCs and cardiomyocytes, culturing PSC-derived cardiomyocytes in glucose-depleted media containing high levels of lactate resulted in pure populations of cardiomyocytes via the selective elimination of PSCs and intermediate differentiated cells (Tohyama et al., 2013) . Similarly, Yoshihara et al. have recently demonstrated that estrogenrelated receptor gamma (ERRg) induced glucose-responsive insulin secretion from PSC-derived beta cells. Forced expression of ERRg in human iPSC-derived beta-like cells induced in vitro maturation and insulin secretion. Furthermore, when these cells were transplanted into beta cell-deficient mice, they rescued the diabetic phenotype (Yoshihara et al., 2016 ). These finding demonstrate the active role of cellular metabolism during differentiation of PSCs to somatic cells and open the door for developing improved in vitro differentiation and maturation protocols based on metabolic reprogramming.
Metabolically characterizing dynamic pluripotent stem cell states, as well as their derivatives, provides unprecedented insights into the metabolic pathways utilized by embryonic cells and, in conjunction with genetic and epigenetic studies, paints a more accurate and complete picture of the molecular landscape of early mammalian development.
Metabolism and Induced Pluripotency
As discussed in the previous section, pluripotent cells are characterized by a glycolytic metabolism associated with high energy demands to sustain rapid cell proliferation, which is vastly different from OXPHOS-driven differentiated cells. Thus, it is not surprising that en route to pluripotency, somatic cells undergo a metabolic remodeling process that accompanies the remarkable transcriptional and epigenetic reprograming. Cellular reprogramming induces a metabolic shift from a highly respiratory metabolism, which depends on mitochondria for ATP production, to a highly glycolytic carbon flux (Folmes et al., 2011; Panopoulos et al., 2012; Varum et al., 2011; Zhang et al., 2012) . Through this conversion, glycolytic processes sustain high rates of cellular proliferation by rapidly generating ATP, whereas mitochondria can mainly be utilized for anabolic processes to produce cellular building blocks.
Although the mechanism of metabolic reprogramming during iPSC generation remains largely unknown, time-course analyses of several molecular features during iPSC generation have revealed a progressive shift in metabolic pathways. By comparing metabolic and gene-expression profiles between mouse iPSC and somatic counterparts, Folmes and colleagues observed increased expression of glycolytic genes and decreased mitochondrial activities in iPSCs (Folmes et al., 2011 (Folmes et al., , 2012 . Similarly, analysis of global metabolic profiles of human iPSCs, ESCs, and fibroblasts echoed the mouse findings (Panopoulos et al., 2012) . Genes participating in the initial and final steps of glycolysis (e.g., Glut1, Hxk2, Pfkm, and Ldha) and the non-oxidative branch of pentose phosphate metabolism were upregulated, likely as a result of the dynamic epigenetic changes during the first stages of reprograming (Folmes et al., 2011; Prigione et al., 2010; Varum et al., 2011) . Additionally, Varum et al. found that PSCs exhibited elevated levels of phosphorylated PDH that block PDH complex activity, resulting in fewer substrates entering the TCA cycle (Varum et al., 2011) . In addition to metabolic pathways, mitochondrial remodeling is also observed during cellular reprograming. For example, mitochondrial respiratory complexes were downregulated and mtDNA copy number and mitochondrial density were reduced, resulting in major functional and structural changes to mitochondria (Prigione et al., 2010; Suhr et al., 2010; Varum et al., 2011) . In addition, the suppression of succinate dehydrogenase complex subunit A (SDHA) by microRNA 31 (miR-31) contributed to the metabolic switch observed during reprogramming . Vazquez-Martin et al. demonstrated that in iPSCs, mitochondrial ATP production was reduced due to increased expression of ATPase inhibitor factor 1 (IF1), which was associated with a drastic decrease in the level of the catalytic b-F1-ATPase subunit (Vazquez-Martin et al., 2012) . These major metabolic changes during cellular reprogramming were driven, in part, by modification of the epigenetic status of genes involved in glycolytic and OXPHOS processes (Panopoulos et al., 2012) . Ultimately, this global metabolic remodeling leads to a progressive transition from somatic oxidative metabolism to glycolysis, as demonstrated by metabolic analyses performed during the reprogramming process, which showed an increase in glycolytic rate and lactate production together with a decrease in cellular respiration (Folmes et al., 2011; Panopoulos et al., 2012; Varum et al., 2011) . Nevertheless, despite this clear transition to a glycolytic state, Mathieu et al. demonstrated that although hypoxia-inducible factors (HIF1a and HIF2a) were required during early stages of reprogramming to initiate the metabolic transition, stabilization of HIF2a during later stages of the process resulted in lower reprogramming efficiency. This is due to the upregulation of TNF-related apoptosisinducing ligand (TRAIL), which represses the apoptotic activity of caspase 3 (Mathieu et al., 2014) . On the other hand, Kida and colleagues recently showed that estrogen-related nuclear receptors (ERRa and ERRg) together with their co-factors PGC-1a and PGC-1b were upregulated at very early stages of reprograming, inducing a burst of OXPHOS (Kida et al., 2015) . Moreover, this oxidative burst seems to be required for cellular reprogramming, as failure to upregulate ERRs decreased the efficiency of cellular reprogramming (Kida et al., 2015) . Similarly, Hawkins et al. have demonstrated that this early burst of OXPHOS and reactive oxygen species leads to an increase in NRF2 activity and the subsequent HIFa activation that drives the metabolic switch during reprogramming to pluripotency (Hawkins et al., 2016) . These recent observations highlight the complexity of the metabolic reprogramming that occurs during the induction of pluripotency, suggesting that this process extends beyond just a simple and direct conversion of respiratory metabolism to glycolysis.
Panopoulos et al. demonstrated, consistent with the metabolic changes observed during cellular reprogramming, higher reprogramming efficiencies for somatic cells with high glycolytic and low oxidative metabolism, where metabolic activities could be more easily converted (Panopoulos et al., 2012) . This suggests the existence of metabolic memory, which may be part of the epigenetic memory observed during iPSC generation. In line with this observation, hypoxia increased reprogramming efficiency by facilitating the metabolic transition necessary to sustain the energetic demands of the pluripotent state (Yoshida et al., 2009 ). Moreover, reprogramming efficiency was also increased by the induction of metabolic switch using D-fluctose-6-phosphate or small molecules (e.g., PS48, which is a potent activator of PDK1 [pyruvate dehydrogenase kinase 1]), which facilitated the metabolic transition from mitochondrial oxidation to glycolysis (Folmes et al., 2011; Zhu et al., 2010) . Similarly, mitochondrial inhibitors (e.g., rotenone, antimycin A, or KCN) increased reprogramming efficiency (Son et al., 2013) . Lastly, expression of oocyte-enriched factor Tlc1 enhanced reprogramming efficiency by suppression of mitochondrial polynucleotide phosphorylase (PnPase) (Khaw et al., 2015) . On the other hand, inhibiting glycolysis via 2-deoxiglucose, 3-bromopyruvic acid, or dichloroacetate blunted reprogramming efficiency by preventing metabolic conversion (Folmes et al., 2011; Panopoulos et al., 2012; Son et al., 2013; Zhu et al., 2010) . Likewise, inhibition of the lipogenic enzymes acetyl-CoA carboxylase (ACACA) or fatty-acid synthase (FASN), which were upregulated in iPSCs, decreased reprogramming efficiency (Vazquez- Martin et al., 2013) . Lastly, whereas chemical inhibition of Drp1 in somatic cells during reprogramming prevented mitochondrial fission (i.e., prevents structural changes to mitochondria) and decreased reprogramming efficiencies (Vazquez-Martin et al., 2012) , depletion of mitofusin 1 and 2 (proteins involved in mitochondrial fusion) facilitated metabolic conversion and increased reprogramming efficiency (Son et al., 2015) . These reports demonstrate that both functional and structural changes to mitochondria play important roles in nuclear reprogramming conferred by pluripotency-related transcription factors. It is intriguing that mitochondria, organelles of bacterial origin, play such a critical role in cellular reprogramming and undergo significant changes during this process. In other words, the remnants of prokaryotic life trapped within our eukaryotic cells seem to exert tremendous control over the fate and identity of our cells. Based on the active role that metabolism plays in cellular reprogramming it will be interesting to investigate whether induction of metabolic changes alone can reprogram cellular identity to a pluripotent state or to a partially dedifferentiated state that will allow tissue healing. Understanding and learning how to control these metabolic changes, which may be happening in vivo during the maintenance of tissue homeostasis or during injury repair, may lead to the development of therapeutic interventions based on metabolic reprogramming.
In summary, significant metabolic changes are observed during cellular reprogramming, including a general metabolic switch from oxidative respiration to glycolysis. This switch is necessary to sustain the energetic demands of pluripotent cells (Figure 2) . Cellular metabolism has historically been considered a complex network of biochemical reactions necessary to sustain life at the molecular level. However, the metabolic transition seen during changes in cellular fate seems to indicate that metabolism plays a very active and dynamic role during reprogramming to pluripotency and may even help drive the reprogramming process. It is therefore interesting that genetic and pharmacological interventions that favor or prevent the transition from mitochondrial respiration to glycolysis can dramatically impact the reprogramming process. It is important to remember, however, that in vitro studies are inherently artificial, particularly when investigating metabolism at 21% oxygen, which could significantly influence our understanding of metabolic changes during transitions between cellular states.
Modeling Metabolic Disease with iPSCs
A practical advantage of iPSCs is their utility as disease models. iPSCs can be generated from somatic cells of patients with metabolic disorders, thereby providing an unlimited experimental resource for studying disease onset and progressions. Primary patient samples have always been critical resources for studying the molecular and pathological mechanism underlying human disorders. However, such samples can be difficult to attain if the disorder affects inaccessible tissues and organs (e.g., the nervous system or the heart), greatly hindering research efforts. This is the case for multiple metabolic disorders, including mitochondrial diseases caused by mtDNA mutations and inborn errors of metabolism. During the past decade, cellular reprogramming has provided numerous iPSC-based models of metabolic diseases in a dish, allowing for the unlimited generation and study of patient-specific cell types (e.g., neurons, cardiomyocytes, and hepatocytes). These models not only provide a novel system for gaining mechanistic understanding of these diseases but also represent an attractive platform for drug screening. Lastly, iPSC-based technologies may lead to the development of cell-replacement therapies to ultimately treat or cure metabolic disorders.
Mitochondria are critical organelles that play fundamental roles in multiple cellular processes, including energy production, calcium homeostasis, cellular signaling, and apoptosis (Dyall et al., 2004) . Mitochondria are double-membraned organelles of bacterial origin that contain their own mtDNA. mtDNA encodes 13 polypeptides of the mitochondrial respiratory chain, as well as tRNAs and rRNAs necessary for their translation (Anderson et al., 1981) . Each mammalian cell contains multiple copies of mtDNA, ranging from $1,000 in somatic cells to several 100,000 in oocytes. Each mitochondrion contains on average 1-10 copies of mtDNA (Shoubridge and Wai, 2007) . Because of the important roles played by mtDNA genes, their mutation often leads to mitochondrial dysfunction, causing a class of metabolic disorders known as mitochondrial diseases. Mitochondrial diseases affect 1 in 5,000 children (Haas et al., 2007) , often resulting in the degeneration of tissues and organs with high-energy demands. Typical clinical phenotypes displayed by patients with mitochondrial diseases include myopathies, cardiomyopathies, and encephalopathies, among others (Taylor and Turnbull, 2005) . Currently, there is no cure for mitochondrial diseases, and palliative approaches to treat symptoms afflicting these patients remain standard of care. Because each cell contains many mitochondrial genomes, mutations affecting mtDNA can be present at different levels and coexist with wildtype mtDNA. The term homoplasmy is used to describe the presence of a single mtDNA haplotype in a particular cell, whereas heteroplasmy refers to the coexistence of more than one mtDNA haplotype. Disease onset and severity primarily depend on the percentage of mutated mtDNA molecules present in the patient's cells. Depending on the mutation and affected gene(s), the level of mutated mtDNA must reach a certain threshold for the manifestation of biochemical and clinical phenotypes. This level is generally 60%-95% (Russell and Turnbull, 2014) .
In the past, mitochondrial diseases have primarily been studied with patient samples such as skin fibroblast. This approach enabled the identification of mtDNA mutations driving these diseases. In addition, generation of patient-specific mitochondrial cybrids (created by the fusion of enucleated patient cells and cancer cell lines devoid of mtDNA) has facilitated functional studies of these diseases (Trounce and Pinkert, 2007) . Despite accumulated knowledge, several notable limitations associated with primary patient samples have precluded deeper mechanistic understanding of this class of metabolic disorders. For example, different tissues may show different susceptibility to specific mtDNA mutations, and therefore disease modeling using the affected primary tissue is more relevant but often lacking when the tissue is limited or inaccessible. Because of this, the generation of iPSCs from mitochondrial disease patients and their differentiation toward affected tissue types represent a superior platform for modeling mitochondrial diseases. Over the last years we and other groups have used cellular reprogramming to generate novel models of a variety of mitochondrial diseases caused by mutations in mtDNA (Table 2) .
Fujikura and colleagues first generated iPSCs from two diabetic patients carrying the mtDNA A3243G heteroplasmic mutation (Fujikura et al., 2012) . Importantly, this mtDNA mutation did not prevent cellular reprogramming, and bona fide iPSCs were successfully established. These cells were genetically stable, expressed markers of pluripotency and were capable of differentiating into cell derivatives of the three germ layers, both in vitro and in vivo. The authors made the important and surprising observation that a bimodal segregation of mutated mtDNA could occur during the course of cellular reprogramming, in which two major classes of iPSC clones that contained either high or undetectable levels of mutated mtDNA were generated (Fujikura et al., 2012) . The authors also reported that total mtDNA content decreased during cellular reprogramming, in agreement with lower mtDNA content observed in PSCs than in somatic cells. However, mitochondrial content and heteroplasmic levels were maintained during iPSC culture and subsequent passages and therefore did not explain the bimodal segregation observed during reprogramming. Although mitochondrial defects were not analyzed in this report, this study raised the intriguing possibility that cellular reprograming of somatic cells carrying mtDNA mutations could serve as a platform for obtaining iPSC with high mtDNA mutation rate for potential use in the following: (1) disease modeling, (2) drug screening, and (3) stochastic correction of mtDNA mutations in mutation-free iPSC clones for potential cell-replacement therapies. Subsequently, Cherry et al. generated iPSCs from a patient with Pearson marrow pancreas syndrome (PS), caused by a 2.5 kb deletion in mtDNA (Cherry et al., 2013) . PS is a hereditary disorder affecting the hematopoietic system by an unknown mechanism, leading to bone marrow failure. Interestingly, although iPSCs with high levels of mutated mtDNA were obtained, levels of mutated mtDNA gradually decreased when these cells were subjected to long-term culture. This eventually led to the generation of mutation-free iPSCs. The reason for this is not clear. One possible explanation is that iPSC clones carrying high mutant content display growth defects, thus providing a growth advantage for iPSCs with less mutated mtDNA (Cherry et al., 2013) . Importantly, iPSCs with high mutation levels, although capable of undergoing differentiation toward hematopoietic lineages, displayed reduced numbers of colony-forming units and increased pathological iron granule deposition in erythroid precursors. These results highlight the recapitulation of tissue-specific phenotypes upon differentiation of iPSCs derived from patients carrying mutations in mtDNA.
Another study by Folmes et al. reported the generation of iPSCs from a patient with MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) carrying a heteroplasmic mitochondrial mutation at position G13513A in the ND5 subunit of complex I (Folmes et al., 2013) . The authors generated three different iPSC lines. Similar to previous reports, two lines displayed high levels of heteroplasmy (50%-60%), whereas the other line was mutation free. Interestingly, independent of the mutation levels, mitochondrial morphology and content were different in iPSCs compared to their somatic counterparts. In agreement with the study by Cherry et al., mutation levels were altered in one of two mutant iPSC lines upon extended culture. In addition, cardiac differentiation was significantly impaired in the iPSC line carrying high levels of mutated mtDNA. Moreover the authors demonstrated that the bimodal segregation of mutant mtDNA during iPSCs generation was, in part, due to mtDNA mosaicism in the starting patient-derived fibroblasts, from which fibroblasts with different levels of heteroplasmy could be clonally isolated. Additionally, alterations in the mitochondrial unfolded protein response (mitoUPR) during cellular reprogramming to pluripotency could lead to changes in the maintenance and propagation of mutated mtDNA. These changes in the level of mtDNA heteroplasmy as consequence of mitoUPR impairment have been recently demonstrated in Caenorhabditis elegans . Consistent with the observations of Folmes et al., Hä mä lä inen and colleagues generated iPSCs from a patient with MELAS carrying the m.3243A>G mutation in the leucine tRNA that causes defect in multiple mitochondrial respiratory complexes (Hä mä lä inen et al., 2013). Similarly, the authors attributed the bimodal separation of mutant versus wild-type mtDNAs to variability in heteroplasmy levels in the original fibroblast population. The authors argued that iPSC generation was accompanied by a reduction in mitochondrial content, mimicking the mtDNA bottleneck seen during epiblast specification (Hä mä lä inen et al., 2013). When iPSC lines with high mutant mtDNA content were differentiated into neurons or teratomas, specific respiratory defects affecting primarily complex I and complex IV were recapitulated. To a lesser extent, this differentiation was accompanied by compensatory upregulation of complex II. Importantly, the authors presented evidence that upon neuronal differentiation, complex I was actively sequestered into PINK-Parkin-positive autophagosomes and degraded. This represented the first example of tissue-specific changes in respiratory activity due to mtDNA mutation and highlighted the power of patient-specific iPSCs for modeling mitochondrial diseases. A third report by Kodaira Rashid et al., 2010 PS, Pearson marrow pancreas syndrome; MELAS, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; LS, Leigh syndrome; GAA, acid alpha-glucosidase; LAMP-2, lysosomal-associated membrane protein type 2; TAZ, tafazzin; a-GalA, a-galactosidase A; GL3, globotriaosylceramide; A1AT, alpha-1 antitrypsin; GSD1, glycogen storage disease type Ia; FH, familial hypercholesterolemia; LDL, low-density lipoprotein.
et al. described the generation of patient-specific iPSCs carrying the same m.3243A>G mutation (Kodaira et al., 2015) . In agreement with the previous studies, reprogramming of MELAS patient cells resulted in the bimodal segregation of mutant mtDNA, and the differentiation of iPSCs carrying high mutant content led to a significant complex I defect in resulting fibroblast. An additional report by the same authors described a novel disease causative mutation in the MT-TW gene at position m.5541C>T in a patient exhibiting MELAS symptoms . After confirming respiratory defects that affect primarily complexes I and IV, the authors generated integration-free iPSC carrying 100% mutant mtDNA. Directed differentiation of mutant iPSCs revealed a significant decrease in differentiation efficiency and loss of CNS and PNS neurons. In contrast, skeletal muscle development was not affected . Once again, these observations are in agreement with the tissue-specific phenotypes observed in patients carrying different mtDNA mutations (Taylor and Turnbull, 2005) . Following a series of reports describing the generation of PSCs from patients suffering from this class of metabolic disorders, our laboratory, in collaboration with the Mitalipov lab, recently generated and characterized PSCs from three patients with mitochondrial disease . First, through cellular reprogramming multiple iPSC clones were generated that carry the 3243A>G mutation, which causes MELAS, or the 8993T>G or 13513G>A mutation, which cause Leigh syndrome. Inconsistent with previous reports, bimodal segregation of mutated mtDNA led to the generation of isogenic iPSCs with high or low mutated mtDNA content. Subsequent analyses of mitochondrial function revealed mitochondrial respiratory defects at the levels of basal and maximal respiration, ATP turnover, and oxidative reserve in MELAS cells (both undifferentiated iPSCs and following differentiation into fibroblasts) . In addition, neuronal progenitor cell (NPC) differentiation recapitulated the diminished metabolic profiles observed in iPSCs and fibroblast, whereas cardiomyocyte differentiation was severely compromised due to massive cell death, possibly from the inability of these cells to sustain the minimum respiratory capacity necessary for differentiation. In the case of homoplasmy, where 100% of mtDNA is mutated, SCNT with a healthy donor oocyte represents the only option for generating diseasefree PSCs. Importantly, we successfully generated mutation-free PSCs from one patient carrying the homoplasmic mtDNA mutation 8993T>G by SCNT . As expected, the nuclear transfer embryonic stem cells (NT-ESCs) exhibited nondetectable levels of mutated mtDNA, and analysis of the mtDNA haplotype confirmed donor-exclusive mtDNA content. Importantly, oxygen flux analysis of NT-ESCs that were differentiated into fibroblast or skeletal muscle demonstrated metabolic rescue (e.g., normal mitochondrial function and ATP production). In addition, RNA-seq analysis of NT-ESCs revealed normal global transcriptional profiles, indicating normal nucleus-tomitochondria communication following SCNT. We consider that this is a critical step toward developing therapeutic approaches for treating patients with mitochondrial disease. Our study highlights the potential of two complementary approaches for generating disease-free PSCs that could be used to develop novel therapeutic interventions for treating patients with mitochondrial disease. Lastly, two recent reports have investigated in a larger number of samples the potential consequences of the increase in the levels of mutated and potentially pathogenic mtDNA genomes during cellular reprogramming to pluripotency. Analysis by next-generation sequencing (NSG) of 84 iPSCs obtained from 19 individuals including mitochondrial patients and healthy subjects demonstrated that mtDNA mutations, which were previously linked to human diseases or with unknown pathological effect, could be revealed during reprogramming (Perales-Clemente et al., 2016) . Importantly, cardiomyocytes differentiated from iPSCs carrying mutated mtDNA, related to mitochondrial disease or previously unknown, showed impaired respiratory capacity (Perales-Clemente et al., 2016 ). An additional study by Kang et al. showed that cellular reprogramming of skin fibroblasts or blood from young and elderly individuals led to the generation of iPSCs with high levels of heteroplasmic or homoplasmic mutations . Importantly, in agreement with the accumulation of mtDNA mutations during aging, the amount of mtDNA mutations leading to potential respiratory defects was higher in iPSCs obtained from samples of old individuals . Both of these reports highlight the importance of deep characterization, including mtDNA integrity, of iPSCs obtained from diseased and healthy individuals particularly at advanced age.
In addition to mitochondrial diseases, iPSC modeling has been applied to another class of metabolic disorders, known as inborn errors of metabolism (IEM). IEMs are often associated with abnormal cellular function in the heart, leading to cardiac dysfunction. To date, iPSCs have been generated from patients suffering from a variety of IEMs, including Pompe disease, Danon disease, Barth syndrome, and Fabry disease (Table 2) . Pompe disease is a glycogen storage disease caused by a complete loss of acid alpha-glucosidase, which is responsible for the hydrolysis of glycogen into glucose, resulting in the abnormal accumulation of glycogen. Huang et al. reported the first iPSC model of Pompe disease. Mutant iPSCs displayed ultrastructural abnormalities and dysfunctional mitochondria. Most importantly, differentiation of iPSCs into cardiomyocytes recapitulated major phenotypes associated with Pompe disease, including accumulation of glycogen, mitochondrial dysfunction, and the formation of autophagosomes (Huang et al., 2011) . Raval et al. used iPSCs to uncover a novel pathophysiologic mechanism underlying the development of Pompe disease, revealing that cardiomyocytes derived from Pompe-disease iPSCs exhibited defects in protein glycosylation within the Golgi (Raval et al., 2015) . Danon disease is another glycogen storage disorder caused by mutations in the LAMP-2 gene, leading to impaired autophagy, skeletal dysfunction, and heart disease. Differentiation of iPSCs derived from two patients with Danon syndrome into cardiomyocytes recapitulated the key features of diseaseassociated heart phenotypes (e.g., cellular hypertrophy, defects in calcium handling, and increased oxidative stress accompanied by defects in autophagy) (Hashem et al., 2015) . These defects were rescued by the overexpression of LAMP-2 or treatment with antioxidants, revealing a potential therapeutic approach for Danon syndrome. In addition to glycogen storage disorders, iPSC modeling of Barth syndrome has also been achieved (Dudek et al., 2013; Wang et al., 2014b) . Barth syndrome is caused by mutations in the phospholipid acyltranferase tafazzin (TAZ), leading to defects in the production of cardiolipin, an essential component of the mitochondrial membrane. These defects in the mitochondrial membrane result in cardiomyopathy, skeletal myopathy, and neurological disorders. Wang et al. described the generation of Barth syndrome iPSCs that recapitulated disease phenotypes, including decreased levels of mature cardiolipin and mitochondrial dysfunction (Wang et al., 2014b) . As expected, restoring wild-type levels of TAZ rescued Barth syndrome iPSC-derived cardiomyocytes and restored sarcomerogenesis. Lastly, cellular reprogramming has also been used to generate iPSC models of the lysosomal storage disorder Fabry disease. Fabry disease is associated with cellular damage to the heart, brain, and kidneys as a consequence of a deficiency in alpha-galactosidase A. Recently, Itier et al. successfully generated iPSCs from two patients with Fabry disease. Cardiomyocytes derived from Fabry iPSCs accumulated globotriaosylceramide (GL-3) in the lysosomes and had disorganized fibers (Itier et al., 2014) . Because enzyme replacement therapy provided only a temporary reduction in GL-3 levels, the authors explored alternative approaches for treating Fabry disease. To this end, they showed that small-molecule inhibitors of glycosphingolipid biosynthesis ameliorated disease phenotypes in cardiomyocytes derived from Fabry disease iPSCs.
In addition to IEM, inherited errors of liver metabolism (IELM) account for significant morbidity in children, with more than 200 liver-based metabolic defects identified. To date, several IELMs, including alpha-1 antitrypsin (AAT) deficiency, glycogen storage disease type Ia (GSD-I), and familial hypercholesterolemia (FH), have been modeled with iPSCs (Table 2) . AAT deficiency is caused by mutations in AAT, resulting in misfolding of the protein and accumulation of protein aggregates in patient hepatocytes. On the other hand, GSD-I is caused by mutations in glucose-6-phosphate, leading to defects in glycogenolysis and gluconeogenesis. Lastly, FH is associated with high plasma levels of low-density lipoproteins (LDL) and increased risk of atherosclerosis and coronary disease. FH results from a hepatic defect in the uptake and degradation of LDL and is usually caused by mutations in the LDL receptor (LDLR). Remarkably, Rashid et al. generated iPSCs from all three of these disorders and further derived patient-specific hepatocytes that secreted albumin and displayed P450 metabolism (Rashid et al., 2010) . Importantly, hepatocytes derived from these disease-specific iPSCs recapitulated key pathological features characteristic of their respective IELM disorder, including aggregation of AAT, elevated lipid and glycogen accumulation, and deficient LDL receptor-mediated cholesterol uptake (Rashid et al., 2010) .
In summary, multiple metabolic disorders, including mitochondrial diseases and inborn errors of metabolism, have been successfully modeled using patient-specific iPSCs. Interestingly, most of these patient samples, regardless of their causative mutations, can be successfully induced into iPSCs, suggesting separated paths taken by differentiation and cellular reprograming. Differentiation of iPSCs toward affected cell types (e.g., neurons, skeletal muscle, cardiomyocytes, and hepatocytes) faithfully recapitulates pathological features observed in patients. This is particularly important if these cells are to be used for drug screening, as the selection of appropriate and disease-representative cell types is perhaps one of the most important criteria. It should be noted that before the discovery of iPSCs, it was not possible to perform highthroughput screening (HTS) using patient-specific cell types, such as neurons, cardiomyocytes, or hepatocytes. Creating patient-specific iPSCs makes it possible to generate a virtually unlimited amount of disease-relevant cell types. We anticipate that the use of cell types more relevant to specific diseases will lead to the discovery of novel small molecules for curing metabolic disorders.
Conclusion
Decades of research with cultured embryos has deeply enriched our understanding of the metabolic pathways regulating preimplantation mammalian development. Likewise, studies of dynamic PSC states and sub-states have provided invaluable information concerning the metabolic changes that occur soon after blastocyst implantation, a period largely inaccessible to conventional experimental manipulation. A metabolic switch from glycolysis to OXPHOS accompanies the differentiation of PSCs toward somatic lineages, a switch that is necessary to maintain highly specialized functions of somatic cells. The discovery of iPSCs has helped to reveal the remarkable plasticity of somatic cells and provided an unprecedented ''reverse development'' platform for dissecting metabolic changes. The generation of iPSCs is marked by a metabolic transition from a somatic bioenergetic program toward a PSC-like metabolic state (i.e., a reversal of PSC differentiation). It should be noted, however, that even though the end points are the same, the molecular/genetic paths taken during PSC differentiation and iPSC generation likely differ, and cellular metabolism likely plays a deterministic role, in that intermediate cells experience distinct microenvironments. Head-to-head comparisons of these reciprocal processes, efforts that would certainly generate novel insights, are currently not possible, largely because PSC differentiation protocols are not perfect and because of the low efficiency of iPSC generation. Because of this and other technical limitations, all existing metabolic profiles are based on cell populations rather than single cells. Thus, it is unclear whether metabolic heterogeneity exists and how this heterogeneity may impact differentiation and cellular reprograming.
In addition to mechanistic studies concerning nuclear reprograming, iPSC generation provides novel avenues for modeling disease, performing drug screens, and developing potential cell-replacement therapies. To date, numerous iPSC-based disease models have been generated, including models of metabolic diseases. Differentiation of iPSC-based disease models into disease relevant cell type is helping us better understand disease initiation and development. When generating iPSCs from patients with mitochondrial disease, mutated mtDNA exhibits bimodal segregation, which makes it possible to generate mutation-free, and therefore disease-free, iPSC clones, as well as iPSC clones that are mutation high. This unique feature provides a perfect set of control and disease isogenic lines for comparative analyses. In addition, the derivation of mutation-free iPSCs in this way obviates the need for using gene-editing technologies, providing a direct source of healthy cells for replacement therapies.
Despite these advances, we are just beginning to understand the integral roles played by cellular metabolism in development and diseases. In light of recent discoveries concerning the interplay between intermediate metabolism and epigenetics, the traditional view of metabolism as a developmental byproduct has largely been refuted. To what extent cellular metabolism is directly wired to cellular transitions associated with development and reprograming warrants future investigations. Hayashi, K., Lopes, S.M.C. de S., Tang, F., and Surani, M.A. (2008) . Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states. Cell Stem Cell 3, 391-401.
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